These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 34277150)
1. NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice. Xie X; Luo C; Liang JY; Huang R; Yang JL; Li L; Li Y; Xing H; Chen H PeerJ; 2021; 9():e11684. PubMed ID: 34277150 [TBL] [Abstract][Full Text] [Related]
2. Role of P2X Yu W; Hill WG; Robson SC; Zeidel ML Sci Rep; 2018 Jan; 8(1):1838. PubMed ID: 29382907 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis. Liu M; Shen S; Kendig DM; Mahavadi S; Murthy KS; Grider JR; Qiao LY J Urol; 2015 May; 193(5):1676-83. PubMed ID: 25572034 [TBL] [Abstract][Full Text] [Related]
4. Urinary dysfunction in transgenic sickle cell mice: model of idiopathic overactive bladder syndrome. Karakus S; Anele UA; Silva FH; Musicki B; Burnett AL Am J Physiol Renal Physiol; 2019 Sep; 317(3):F540-F546. PubMed ID: 31215803 [TBL] [Abstract][Full Text] [Related]
12. Functional characterization of a chronic cyclophosphamide-induced overactive bladder model in mice. Boudes M; Uvin P; Kerselaers S; Vennekens R; Voets T; De Ridder D Neurourol Urodyn; 2011 Nov; 30(8):1659-65. PubMed ID: 21717507 [TBL] [Abstract][Full Text] [Related]
13. Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2. Javed E; Thangavel C; Frara N; Singh J; Mohanty I; Hypolite J; Birbe R; Braverman AS; Den RB; Rattan S; Zderic SA; Deshpande DA; Penn RB; Ruggieri MR; Chacko S; Boopathi E FASEB J; 2020 Feb; 34(2):2126-2146. PubMed ID: 31909533 [TBL] [Abstract][Full Text] [Related]
14. Effect of silymarin on bladder overactivity in cyclophosphamide-induced cystitis rat model. Eser N; Göçmen C; Erdoğan S; Büyüknacar HS; Kumcu EK; Açıkalın A; Önder S Phytomedicine; 2012 Jun; 19(8-9):840-5. PubMed ID: 22647456 [TBL] [Abstract][Full Text] [Related]
15. Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. Hao Y; Wang L; Chen H; Hill WG; Robson SC; Zeidel ML; Yu W JCI Insight; 2019 Aug; 4(16):. PubMed ID: 31434806 [TBL] [Abstract][Full Text] [Related]
16. Role of ecto-5'-nucleotidase in bladder function. Barge S; Wu A; Zhang L; Robson SC; Olumi A; Alper SL; Zeidel ML; Yu W FASEB J; 2024 Jan; 38(2):e23416. PubMed ID: 38198186 [TBL] [Abstract][Full Text] [Related]
17. Suppression of adenosine A Yang Y; Zhang H; Lu Q; Liu X; Fan Y; Zhu J; Sun B; Zhao J; Dong X; Li L Biochem Pharmacol; 2021 Jan; 183():114340. PubMed ID: 33189675 [TBL] [Abstract][Full Text] [Related]
18. A new model of detrusor overactivity in conscious rats induced by retinyl acetate instillation. Wróbel A; Łańcut M; Rechberger T J Pharmacol Toxicol Methods; 2015; 74():7-16. PubMed ID: 25957030 [TBL] [Abstract][Full Text] [Related]
19. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424 [TBL] [Abstract][Full Text] [Related]
20. Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Kageyama A; Fujino T; Taki Y; Kato Y; Nozawa Y; Ito Y; Yamada S Neurosci Lett; 2008 May; 436(1):81-4. PubMed ID: 18372110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]